Spectrum of Bacterial Infection and Antibiotic Susceptibility Profile among Clinical Samples of Febrile Pediatric Cancer Patients under Chemotherapy
DOI:
https://doi.org/10.61841/0t7tjg34Keywords:
Febrile Pediatric CancerAbstract
Bacterial infection is one of the most frequent complications in malignant patients. Among them, those caused by multidrug-resistant (MDR) bacteria that increase mortality and morbidity mainly because of limited therapeutic options. The study material comprised 155 febrile episodes occurring in 101 children aged less than 18 years with various malignancies from May 2018 to April 2019 at Basrah Children's Specialty Hospital. All the episodes were worked up in detail, including physical examination, history, and relevant investigations. Bacterial isolated from different sites were identified to the species level and tested for their susceptibility to a variety of antimicrobial agents A total of 61 bacteria were cultured in 155 febrile episodes. Gram-negative bacteria were more prevalent (53 [86.9%]) as a cause of infection in febrile pediatric cancer patients at our institution. Escherichia coli showed the highest isolation rate, 64.1% (34/53), followed by Klebsiella pneumoniae, 13.2% (7/53), and Proteus mirabilis, 11.3% (6/53). The rate of MDR in Gram-negative isolates was 90.5% (48/53). Gram-positive consists of 8 (13.1%) with a prevalence of Staph aureus of 37.5% (3/8) and a rate of MDR of 75% (6/8). The antibiotic susceptibility results showed meropenem, imipenem, and amikacin to be the most effective antibiotics for Gram-negative bacteria. Overall, urinary tract infections were the most common sites of infection (23.2%). The results of the analysis of the sequencing of 16SrDNA of selected 43 isolates showed 100% compatibility at the genus and species level with the results of VITEK 2. Ten isolates were registered as a new strain in Gene Bank. Gram-negative bacteria with high MDR were the more prevalent cause of infection in febrile pediatric cancer patients. Escherichia coli is the most common pathogen. The changing pattern of infectious agents in cancer patients with significant distribution of MDR suggests the need for further studies to give physicians a more recent view of bacterial isolates and antibiotic resistance patterns for appropriate therapeutic approaches.
Downloads
References
[1] Eldomany R. and Abdelaziz N A. “Characterization and antimicrobial susceptibility of gram negative bacteria Isolated from cancer patients on chemotherapy in Egypt” Archives of clinical Microbiology 2011; 2(6): 1 -13.
[2] de Oliveira Costa, P., Atta, E. H., & da Silva, A. R. A. Infection with multidrug‐resistant gram‐negative bacteria in a pediatric oncology intensive care unit: risk factors and outcomes. Jornal de Pediatria (Versãoem Português) 2015; 91(5): 435-441.
[3] Kuo, F.C., Wang, S.M., Shen, C.F., Ma, Y.J., Ho, T.S., Chen, J.S., Cheng, C.N. and Liu, C.C., 2017. Bloodstream infections in pediatric patients with acute leukemia: Emphasis on gram-negative bacteria infections. Journal of Microbiology, Immunology and Infection 2017;50(4): 507-513.
[4] Zembower T.R. Epidemiology of Infections in Cancer Patientsin Stosor
V and Zembower Tr, Infectious Complications in Cancer Patients, Cancer Treatment and research 161.
Springer International Publishing CH. 2014; P: 43–89
[5] Sbrana, A., Torchio, M., Comolli, G., Antonuzzo, A., &Danova, M. Use of procalcitonin in clinical
oncology: a literature review. New Microbiol 2016; 39(3):174-180.
[6] Pizzo, P. A. Fever in immunocompromised patients. New England Journal of Medicine 1999; 341(12):
893-900.
[7] Perdikouri, E. I. A., Arvaniti, K., Lathyris, D., Apostolidou Kiouti, F., Siskou, E., Haidich, A. B., &
Papandreou, C.. Infections due to multidrug-resistant bacteria in oncological patients: Insights from a fiveyear epidemiological and clinical analysis. Microorganisms 2019; 7(9): 1-13.
[8] Katsogridakis L, Cieslak L Empiric Antibiotics for the Complex Febrile Child When, Why, and What to
Use. MD ClinPed Emerg Med 2008;9:258-263.
[9] Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk
method. Am J ClinPathol. 1966;45(4):493–496.
[10] CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI supplement M100.
Wayne, PA: Clinical and Laboratory Standards Institute; 2018
[11] Miyoshi T, Iwatsuki T, Naganuma T. Phylogenetic Characterization of 16s rDNA Gene Clones from DeepGroundwater Microorganisms That Pass through 0.2-Micrometer-Pore-Size Filters. Applied and
environmental microbiology 2005; 71(2): 1084-1088
[12] Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., Harbarth, S.,
Hindler, J.F., Kahlmeter, G., Olsson‐Liljequist, B. and Paterson, D.L. Multidrug‐resistant, extensively
drug‐resistant and pandrug‐resistant bacteria: an international expert proposal for interim standard
definitions for acquired resistance. Clinical microbiology and infection 2012; 18(3): 268-281.
[13] Kapoor, G., Sachdeva, N., Jain, S. Epidemiology of bacterial isolates among pediatric cancer patients from
a tertiary care oncology center in North India. Indian journal of cancer 2014; 51(4): 420- 424
[14] Sirkhazi, M., Sarriff, A., Aziz, N. A., Almana, F., Arafat, O., &Shorman, M. Bacterial spectrum, isolation
sites and susceptibility patterns of pathogens in adult febrile neutropenic cancer patients at a specialist
hospital in Saudi Arabia. World journal of oncology 2014; 5(5-6): 196- 203
[15] Collin BA, Leather HL, Wingard JR. Evolution, incidence, and susceptibility of bacterial bloodstream
isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33: 947–953.
[16] Meidani M, Rostami M, Moulaee S. Blood culture in neutropenic patients with Fever. Int J Prev Med.
2012;3(2):141-142.
[17] Sandoval, C., Sinaki, B., Weiss, R., Munoz, J., Ozkaynak, M. F., Tugal, O., &Jayabose, S. Urinary tract
infections in pediatric oncology patients with fever and neutropenia. Pediatric hematology and oncology
2012; 29(1): 68-72.
[18] Al-Mulla NA, Taj-Aldeen SJ, El Shafie S, Janahi M, Al-Nasser AA, Chandra P. Bacterial bloodstream
infections and antimicrobial susceptibility pattern in pediatric hematology/oncology patients after
anticancer chemotherapy. Infect Drug Resist. 2014;7:289–299.
[19] Abdul-Ridha, L. A. H., & Al-Abbas, M. J. Clinical Characteristics, Etiology and Phylogenetic Distribution
of Bacteremia in Patients with Malignancies in Basrah Province. International Journal of Science 2016; 5
(11):76- 86.
[20] Gudiol, C., Bodro, M., Simonetti, A., Tubau, F., González-Barca, E., Cisnal, M., Domingo-Domenech, E.,
Jiménez, L. and Carratalà, J. Changing aetiology, clinical features, antimicrobial resistance, and outcomes
of bloodstream infection in neutropenic cancer patients. Clinical Microbiology and Infection 2013; 19(5):
474-479.
[21] Khaparkuntikar, M, Siddiqui, N and Bhirud, Prasanna. Urinary Tract Infection in Cancer Patients at
Government Cancer Hospital Aurangabad, India. International Journal of Current Microbiology and
Applied Sciences ISSN 2017;6(5): 2259-2263
[22] Kar, Y. D., Özdemir, Z. C., &Bör, Ö. Evaluation of febrile neutropenic attacks of pediatric hematologyoncology patients. Turkish Archives of Pediatrics 2017; 52: 213-220
[23] Fazeli, H., Moghim, S., Zare, D. Antimicrobial resistance pattern and spectrum of multiple-drug-resistant enterobacteriaceae in Iranian hospitalized patients with cancer. Advances in Biomedical Research 2018; 7,69.
[24] Hughes, W.T., Armstrong, D., Bodey, G.P., Bow, E.J., Brown, A.E., Calandra, T., Feld, R., Pizzo, P.A., Rolston, K.V., Shenep, J.L. and Young, L.S. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases 2002;34:730–751.
[25] Klaassen, I. L. M., de Haas, V., van Wijk, J. A. E., Kaspers, G. J. L., Bijlsma, M., &Bökenkamp, A. Pyuria
is absent during urinary tract infections in neutropenic patients. Pediatric blood & cancer 2011; 56(5): 868-
870.
[26] Hirmas, N., Mubarak, S., & Sultan, I. Patterns of microbial growth in urine cultures in a pediatric
hematology/oncology unit over a one-year period: a single institution study. International Journal of
Pediatrics and Adolescent Medicine 2017; 4(3), 95-99.
[27] Zorgani, A. A., Belgasim, Z., Ziglam, H., &Ghenghesh, K. S. Antimicrobial susceptibility profiles of gramnegative bacilli and gram-positive cocci isolated from cancer patients in Libya. Archives of Clinical
Microbiology 2012;3(3.3): 1-8
[28] Swati, M., Gita, N., Sujata, B., Farah, J., &Preeti, M. (2010). Microbial etiology of febrile
neutropenia. Indian Journal of Hematology and Blood Transfusion, 26(2), 49-55.
[29] Yadegarynia, D., Fatemi, A., Mahdizadeh, M., Movahhed, R. K., &Alizadeh, M. A. Current spectrum of
bacterial infections in patients with nosocomial fever and neutropenia. Caspian J Intern Med 2013; 4(3):
698-701
[30] Hagag AA, Hassan SM, Elgamasy MA, Afifi IK. Study of Common Bacterial and Fungal Pathogens in
Children with Hematological Malignancies during Febrile Neutropenia: Single Center Egyptian Study.
Infect Disord Drug Targets 2016; 16 (1): 54-62.
[31] Fentie, A., Wondimeneh, Y., Balcha, A., Amsalu, A., &Adankie, B. T. Bacterial profile, antibiotic
resistance pattern and associated factors among cancer patients at University of Gondar Hospital,
Northwest Ethiopia. Infection and drug resistance 2018; 11; 2169–2178.
[32] Chong Y, Yakushiji H, Ito Y, Kamimura T. Cefepimeresistant Gram-negative Bacteremia in Febrile
Neutropenic Patients with Hematological Malignancies. Int J Infect Dis 2010; 14(Suppl 3) : e171-175.
[33] Oude Nijhuis CS, Daenen SM, Vellenga E, van der Graaf WT, Gietema JA, Groen HJ, Kamps WA, de
Bont ES (2002). Fever and Neutropenia in Cancer Patients: The Diagnostic Role of Cytokines in Risk
Assessment Strategies. Critical reviews in oncology/hematology2002; 44(2); 163-174.
[34] Saeidpour M, Hamedi AK, Hanachi P. Pattern of Bacterial and Fungal Infections in Neutropenic Pediatric
Patients. Iran J Med Sci 2008; 33(4) : 202-208.
[35] Cattaneo, C., Quaresmini, G., Casari, S., Capucci, M.A., Micheletti, M., Borlenghi, E., Signorini, L., Re,
A., Carosi, G. and Rossi, G. Recent changes in bacterial epidemiology and the emergence of
fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a
prospective study on 823 patients at a single institution. Journal of antimicrobial
chemotherapy2008; 61(3):721-728.
[36] Nejad ZE, Ghafouri E, Farahmandi-Nia Z, Kalantari B, Saffari F. Isolation, identification, and profile of
antibiotic resistance of bacteria in patients with cancer. Iran J Med Sci 2010; 35 (2): 109-115
[37] Al-naimi,I,A and Abbas,M,A. Recurrent urinary tract infections in Iraqi leukemic patients. International
Journal of Advanced Research 2016; 4 (3): 1433-1439
[38] Wenzel, R. P., Sahm, D. F., Thornsberry, C., Draghi, D. C., Jones, M. E., &Karlowsky, J. A. In vitro
susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries,
Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator
antimicrobials: implications for therapy. Antimicrobial agents and chemotherapy2003; 47(10), 3089-3098.
[39] Spanu, T., Luzzaro, F., Perilli, M., Amicosante, G., Toniolo, A., Fadda, G., & Italian ESBL Study Group.
Occurrence of extended-spectrum β-lactamases in members of the family Enterobacteriaceae in Italy:
implications for resistance to β-lactams and other antimicrobial drugs. Antimicrobial agents and
chemotherapy 2002; 46(1): 196-202.
[40] Ashour, H. M., & El-Sharif, A. Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients. Journal of translational medicine 2009; 7: 1-13.
[41] Pfaller, M. A., & Jones, R. N. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. Journal of Antimicrobial Chemotherapy2000; 46(suppl_2), 25-37.
[42] Goossens, H. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. Journal of Antimicrobial Chemotherapy 2000; 46(suppl_2): 39-52.
[43] Jones, R. N. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001; 119(2), 397S-404S.
[44] Seif El-Din S, El-Rehewy M S, Ghazaly M M, Abd-Elhamid M H. Biofilm Formation by Blood Stream
Staphylococcal Isolates from Febrile Pediatric Cancer Patients at South Egypt Cancer Institute. Journal of
American Science 2011; 7(1):674-686.
[45] Glasmacher A and von Lilienfeld M.An evidence based review of the available antibiotic treatment options
for neutropenic patients and a recommendation for treatment guidelines. Int J Infect Dis. 2006; 10(S2):S9–
S16.
[46] Montassier, E., Batard, E., Gastinne, T., Potel, G., & de La Cochetière, M. F. Recent changes in bacteremia
in patients with cancer: a systematic review of epidemiology and antibiotic resistance. European journal of
clinical microbiology & infectious diseases2013; 32(7): 841-850.
[47] Abd Al-Wahid, Z, H & Al-Abbas, M. J.Detection of E.Coli Strains Isolated from Water Sources and
Diarrhea Cases by Random Amplified Polymorphic DNA in Basrah Governorate.International Journal of
Sciences2019; 8(0.3), 68- 83.
[48] Rampini, S. K., Bloemberg, G. V., Keller, P. M., Büchler, A. C., Dollenmaier, G., Speck, R. F., &Böttger, E. C. Broad-range 16s rDNA gene polymerase chain reaction for diagnosis of culture-negative bacterial infections. Clinical Infectious Diseases 2011; 53(12): 1245-1251.
[49] Bosshard, P. P., Zbinden, R., Abels, S., Böddinghaus, B., Altwegg, M., &Böttger, E. C. (2006). 16s rRNA gene sequencing versus the API 20 NE system and the VITEK 2 ID-GNB card for identification of nonfermenting Gram-negative bacteria in the clinical laboratory. Journal of clinical microbiology2006; 44(4): 1359-1366.
[50] Abd Al-Abbas, M. J. “Antimicrobial Susceptibility of Enterococcus faecalis and a Novel Planomicrobium Isolate of Bacterimia.” International Journal of Medicine and Medical Sciences 2012; 4 (2): 19–27.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
